Recombinant Human ACE2 Fusion Protein

Soluble ACE2 protein with Fc-tag in C-terminal | SARS-CoV-2 cellular receptor

ABOUT

SARS-CoV-2 cellular receptor: Soluble ACE2 fused to an IgG1 Fc domain

Human ACE2 (angiotensin I-converting enzyme-2) is a Type I surface transmembrane protein expressed in arteries, heart, kidneys, and epithelia of the lung and small intestine [1, 2]. ACE2 belongs to the angiotensin-converting enzyme family of dipeptidyl carboxydipeptidases [2, 3].
ACE2 also plays a critical role in the human pathogenesis of the coronavirus disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, or 2019-nCoV). Indeed, hACE2 is now established as the receptor for the Spike (S) protein of the SARS-CoV and SARS-CoV-2 coronaviruses, facilitating the viral entry into target cells [4-6]. The blockade of the ACE2 receptor and the delivery of an excessive soluble form of ACE2 are among the investigated strategies to treat COVID-19.


The soluble hACE2-Fc protein was generated by fusing the C-terminus of the human ACE2 extracellular domain [M1-S740] to a human IgG1 Fc region.
This protein has been produced in CHO cells and purified by affinity chromatography.

Applications

  • SARS-CoV and SARS-CoV-2 neutralization assays
  • Screening of small molecules inhibitors or of neutralizing antibodies able to block Spike-RBD and ACE2 interaction

Quality control

  • Size and purity confirmed by SDS PAGE
  • Protein validated by ELISA upon incubation with a coated Spike-RBD-His protein and an Anti-human IgG1-HRP detection antibody

 

Learn more on SARS-CoV-2 Learn more about SARS-CoV-2 infection cycle, immune responses, and potential therapeutics.

 

References

1. Harmer D. et al., 2002. Quantitative mRNA expression profiling of ACE2, a novel homolog of angiotensin-converting enzyme. FEBS Letters. 532(1-2):107-110.
2. Hamming I. et al., 2004. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. J. Pathol. 203:631-637.
3. Donoghue M. et al., 2000. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Cir. Research. 87(5):e1-e9.
4. Li W. et al., 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426(6965):450-454.
5. Hoffmann M. et al., 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:1-16.
6. Zhou P. et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579(7798):270-273.

All InvivoGen products are for internal research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Source
CHO cells
Species
Human
Accession sequence

AAQ89076

Protein size
967 a.a. (secreted form)
Molecular weight
~130 kDa (SDS PAGE)
Tag
Fc, C-ter
Purity
>95% (SDS-PAGE)
Formulation buffer

Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free water (provided)
Endotoxin

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.

Tested applications

SARS-CoV and SARS-CoV-2 neutralization assays, ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    hACE2-Fc
  • Cat code: 
    fc-hace2
  • Quantity: 
    50 µg
Includes:

1.5 ml of endotoxin-free water

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20 °C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

ACE2 is a metalloproteinase that cleaves angiotensin I to angiotensin 1-9 and angiotensin II to form angiotensin 1-7, as well as other peptides unrelated to the angiotensin system [1, 2]. ACE2 is thought to be an essential regulator of cardiac function and blood pressure [1].

Human ACE2 has also been described as a receptor for the Spike (S) protein of the SARS-CoV and SARS-CoV-2 coronaviruses, facilitating the viral entry into target cells [3-6]. SARS-CoV and SARS-CoV-2 share most of the amino acid residues essential for ACE2 binding within their Spike receptor-binding domain (RBD) [5]. Of note, SARS-CoV-2 is able to use human, Chinese horseshoe bat, civet, and pig ACE2, but not murine ACE2, to enter cells [6].

SARS-CoV-2 entry into ACE2-expressing cells also depends on the concerted action of host proteases. While the exact timing and location for these processes to take place remain to be determined, it has been proposed that the S protein is cleaved into two subunits (S1 and S2) by proteases, including furin and TMPRSS2 [5, 7]. S1 binds to ACE2 and S2 is further cleaved and activated by the host surface-associated transmembrane protease serine 2 (TMPRSS2) [5, 7]. Together these actions result in host-viral membrane fusion and the viral RNA genome is released into the host cell cytoplasm.

Human ACE2 is currently investigated among therapeutic strategies to fight SARS-CoV and SARS-CoV-2 infections [8-10].


References

1. Donoghue M. et al., 2000. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Cir. Research. 87(5):e1-e9.
2. Harmer D.  et al., 2002. Quantitative mRNA expression profiling of ACE2, a novel homolog of angiotensin-converting enzyme. FEBS Letters. 532(1-2):107-110.
3. Hamming I.  et al., 2004. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. J. Pathol. 203:631-637.
4. Li W.  et al., 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426(6965):450-454.
5. Hoffmann M.  et al., 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:1-16.
6. Zhou P.  et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579(7798):270-273.
7. Walls A.C.  et al., 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 181(2):281-292.e6.
8. Zhang H.  et al., 2020. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine. 46(4):586-590.
9. Monteil V. et al., 2020. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 181:1-9.
10. Lei C. et al., 2020. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat. Comm. 11(1):2070.

DOCUMENTS

Documents

hACE2-Fc

Technical Data Sheet

Validation Data Sheet

Plasmid Sequence

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?